Source link : https://newshealth.biz/health-news/first-twice-yearly-biologic-approved-for-severe-eosinophilic-asthma/
(MedPage Today) — The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The subcutaneous anti-interleukin… Source link : https://www.medpagetoday.com/allergyimmunology/asthma/119054 Author : Publish date : 2025-12-17 13:56:00 Copyright for syndicated content belongs to the linked Source.
The post First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-17 13:56:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8